Skip to main content

Table 3 Values obtained before TCZ initiation and after the last infusion for each patient

From: Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever

Patients Age (year) Sex Comorbid diseases Disease duration (year) Amyloidosis duration (year) Number of applieddoses Previous biotherapies Creatinine before treatment (mg/dl) Creatinine after treatment (mg/dl) GFR before treatment (ml/min) GFR after treatment (ml/min) Proteinuria before treatment (mg/day) Proteinuria after treatment (mg/day) CRP before treatment (0–5 mg/L) CRP after treatment (0–5 mg/L) Sedimentation before treatment (mm/h) Sedimentation after treatment (mm/h) MEFV gene mutation
1 36 M 0 1 1 6 - 3.24 2.4 37.52 45.14 12000 2072 1.5 0.3 32 7 M694V/R761H compound heterozygote
2 44 M 0 27 1 5 Anakinra 2.58 1.86 39.94 59 23677 14962 11.5 2.73 107 43 M694V homozygote
3 45 M AS 28 0.58 31 Canakinumab 1.28 1.12 86.83 98.72 4725 4462.5 25.5 13.23 32 8 M694Vhomozygote-R202Q homozygote
4 47 F 0 14 0.41 31 - 0.8 0.83 80.84 82.76 2100 1440 14.7 0.31 24 1 M694Vhomozygote-R202Q homozygote
5 23 M 0 15 1 4 - 0.69 0.71 184.9 192.16 3038.5 1392 15.7 14 20 8  
6 35 M AS 28 10 28 Infliximab 1.18 1.4 92 81.71 1715.6 2720 13.5 0.72 7 3 M694Vhomozygote-R202Q homozygote
7 41 F 0 17 16 13 Cyclophosphamide 0.72 0.65 116 106.2 3000 1950 9.2 10.14 75 40 M694V homozygote
8 39 F CROHN DISEASE, AS 7 7 32 Infliximab, Cyclophosphamide, Anakinra, Canakinumab 0.43 0.55 136.6 96 1588 740 9.8 21.5 50 40 M694V homozygote
9 24 F 0 20 3 4 Anakinra 0.4 0.36 166.6 225.89 6018 4707 69.7 3.5 69 61 M694V homozygote
10 22 F 0 8 1 20 - 0.39 0.5 175.02 133 1827 80 40 0.42 89 3 MEFV −/−
11 45 F AS 8 3 6 Anakinra, Infliximab, Etanercept, Canakinumab 0.8 0.93 80.7 54.3 7061.76 5680 4.4 1.6 56 91 M680Iheterozygote-M694Vheterozygote
12 21 M 0 7 3 4 Anakinra 0.83 0.85 143.6 132.22 11700 16740 1.31 1.42 23 29 M694V/N heterozygote